Companies Immutrin

Antibodies to clear aggregated proteins


Abnormal aggregation of proteins in tissues are the cause of many conditions that lead to deteriorating health.

From type 2 diabetes and Alzheimer’s, through to many forms of rarer conditions (known as systemic amyloidioses), Immutrin is seeking to create a novel therapy capable of treating them all. Immutrin is the product of two eminent academics, Professor Sir Mark Pepys FRS and Nobel Laureate, Sir Greg Winter FRS.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More